Last reviewed · How we verify
NCT04045522
Study on Bisphosphonates Targeting Triple-negative Breast Cancer
trial testing Zoledronic Acid in Breast Cancer in 120 participants. Status unknown.
31 August 2021
Quick facts
| Lead sponsor | Shengjing Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 120 |
| Start date | 1 September 2019 |
| Primary completion | 31 August 2021 |
| Estimated completion | 31 August 2022 |
| Sites | 3 locations across China |
Drugs / interventions tested
- Zoledronic Acid (ZOLEDRONIC ACID) — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Shengjing Hospital
Who can join
Adults 55 to 70, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Triple-negative breast cancer has a poor prognosis and lacks effective adjuvant treatment. A number of preclinical and clinical trials have shown that bisphosphonates have direct or indirect anti-tumor activity, and early use of bisphosphonate adjuvant therapy can prevent cancer recurrence and metastasis including bone metastasis and greatly improve the prognosis of cancer patients. Bisphosphonates have the advantages of low cost, low toxicity, and strong tolerance and can be used as an auxiliary treatment for triple-negative breast cancer. The preliminary study found that bisphosphonates can be chimeric with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, which can synergistically inhibit the in vitro tumor formation of cancer (such as non-small-cell lung cancer and breast cancer) cells and the growth of transplanted tumors. Therefore, the purpose of this multi-center prospective real-world study was to further investigate the effects of bisphosphonate adjuvant therapy on breast cancer.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Drug Repurposing for Triple-Negative Breast Cancer.
Ávalos-Moreno M, López-Tejada A, Blaya-Cánovas JL, Cara-Lupiañez FE, et al · · 2020 · cited 26× · PMID 33138097 · DOI 10.3390/jpm10040200 -
Macrophages: Key Players in the Battle against Triple-Negative Breast Cancer.
Padzińska-Pruszyńska I, Kucharzewska P, Matejuk A, Górczak M, et al · · 2024 · cited 8× · PMID 39409110 · DOI 10.3390/ijms251910781
Verify or expand the search:
- PubMed search for NCT04045522
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Zoledronic Acid
Trials testing the same drug.
- NCT05666310 — Muscle Impact of Treating Osteoporosis · Phase 4 · active not recruiting
- NCT04597931 — Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density · Phase 4 · unknown
- NCT04736693 — Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data · completed
- NCT04087096 — Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery · Phase 4 · completed
- NCT04303026 — The Effect of Zoledronic Acid on Patients With Osteoarthritis of the Hip · Phase 3 · unknown
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Shengjing Hospital trials
Trials by the same sponsor.
- NCT07484763 — Predicting Recurrence in HR+/HER2- Early Breast Cancer · not yet recruiting
- NCT07497191 — AMH Dynamic Changes to Predict Ovarian Reserve in Perimenopausal Breast Cancer · not yet recruiting
- NCT07320599 — Neuroendoscopic Surgery With Ommaya Reservoir Implantation vs. Burr Hole Drainage for Infantile Postmeningitis Subdural · not yet recruiting
- NCT07153783 — Interventional AI-Human Collaboration for Liver Tumor Diagnosis · NA · completed
- NCT07101614 — A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chem · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04045522 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shengjing Hospital
- Last refreshed: 20 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04045522.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing